Alembic Pharma to raise funds via QIP

27 July 2020

Alembic Pharmaceuticals (BSE: 533573) has received board approval to raise $150-$200 million through a qualified institutions placement (QIP) issue of shares.

The Indian generic drugmaker launched 22 generic drugs in the USA in the previous fiscal year, with a further 10 products planned in the first half of the current financial year.

For the quarter, Alembic Pharma reported strong revenue growth of 41.4% YoY (up 11.1% QoQ) led by strong growth in the international markets, especially that of the USA. The US business brings in about 54% of the firm’s revenue.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK